Immunitybio Inc (IBRX) Stock AnalysisIBRXImmunitybio Inc

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

ImmunityBio Inc (IBRX) is a good buy right now due to its current price of $8.05, which is significantly lower than the analyst price target of $12, indicating a potential upside of 49%. Additionally, the stock has shown a remarkable year-to-date change of +298.51%, reflecting strong investor interest and momentum. The main risk is the negative net income, which reached -632,782,000 USD in Q1 2026, highlighting ongoing financial challenges that investors should monitor closely.